Intellia Therapeutics, Inc. NTLA NASDAQ

Intellia Therapeutics, Inc. (NTLA) generated $-348.88M in operating cash flow for fiscal year 2025. After capital expenditures of $5.78M, free cash flow was $-354.66M.

Free cash flow margin was -524.1% of revenue. Cash conversion ratio was 0.67x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (47/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.67x suggests some earnings are non-cash items

Overall SharesGrow Score: 57/100 with 4/7 criteria passed.